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Abstract 
 
Background: There is growing interest in the potential for wearable and mobile devices to deliver 
clinically relevant information in real-world contexts. However, there is limited information on their 
acceptability and barriers to long-term use in people living with psychosis.  
 
Objective: We describe the development, implementation, feasibility, acceptability and user-
experiences of the Sleepsight platform, which harnesses consumer wearable devices and 
smartphones for the passive and unobtrusive capture of sleep and rest-activity profiles in people 
with schizophrenia, living in their homes.  
 
Methods: Fifteen outpatients with a diagnosis of schizophrenia used a consumer wrist-worn device 
and smartphone to continuously and remotely gather rest-activity profiles over two months. Once-
daily sleep and self-rated symptom diaries were also collected via a smartphone application. 
Adherence with the devices and smartphone application, end of study user-experiences and 
agreement between subjective and objective sleep measures were analysed. Thresholds for 
acceptability were set at a wear-time or diary response rate of 70% or greater. 
 
Results: 14/15 participants completed the study. In individuals with a mild to moderate symptom 
severity at baseline (mean total PANSS score 58.4 (SD = 14.4)), we demonstrated high rates of 
engagement with the wearable device (all participants meeting acceptability criteria), sleep and 
symptom diary (93% and 86% meeting criteria, respectively), with negative symptoms being 
associated with lower diary completion rate. The end of study usability and acceptability 
questionnaire and qualitative analysis identified facilitators and barriers to long-term use, and 
paranoia with study devices was not a significant barrier to engagement. Comparison between 
sleep-diary and wearable estimated sleep times showed good correspondence (r = 0.50, P < .001).   
 
Conclusions: Extended use of wearable and mobile technologies are acceptable to people with 
schizophrenia living in a community setting. In the future, these technologies may allow predictive, 
objective markers of clinical status, including early markers of impending relapse. 
 
Keywords 
 
Sleep, circadian rhythm, rest-activity, mHealth, wearables, Fitbit, smartphone, relapse, psychosis  
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Introduction  
 
Approximately 80% of those treated for a first-episode of psychosis experience at least one further 
episode within five years[1]. Relapse often goes undetected until the individual is severely unwell, 
by which time the episode is disabling, distressing, and compromises illness trajectory[2]. 
Developing systems for detecting the early signs of deterioration[3] and prompting preventative 
interventions that avert relapse and hospital admission, are therefore a priority. 
 
Disturbances in rest-activity patterns are frequently reported in the early stages of relapse in 
schizophrenia. Sleep disturbance is the most common relapse indicator to be identified by family 
members[4], and are reported by 68%[5] to 79%[6] of patients. They commonly precede relapse by 
over a week[5], suggesting they occur in the early stages of deterioration. Insomnia, sleep 
fragmentation and reduced total sleep time have been associated with severity of psychotic 
experiences[7-9], and recent evidence suggests sleep disruption may play a causal role in the 
genesis of psychotic symptoms[10, 11]. Similarly, the organisation of motor activity has been 
shown to vary with severity of psychotic symptoms[12, 13]. Sleep and rest-activity disturbance 
therefore appear to be an important, objective early sign of deterioration in clinical status.  
 
Rest-activity profiles across phases of illness are poorly characterised, in part due to the 
challenges of sampling these rhythms over long periods in individuals with psychosis. To date, 
objective estimation of  sleep under free-living conditions has been derived from wrist-
actigraphy[14, 15], which estimates sleep parameters from patterns of rest-activity[16]. Actigraphy 
typically lacks wireless capability, thereby necessitating home or clinic visits for the manual 
download of data, and precluding the real-time data upload necessary for triggering preventative 
interventions. Actigraphs are recognisable as clinical devices, which can be stigmatising and 
aesthetically unacceptable to the user[17], and limits their suitability for applications where long-
term use in naturalistic settings is required. 
 
The case for wearable and mobile technologies  
 
Recent advances in consumer wearable technology offer several advantages over actigraphy for 
the remote, continuous and unobtrusive sampling of rest-activity patterns across phases of illness, 
in ecologically valid settings. Marketed as lifestyle devices for improving health and wellbeing, they 
are designed to be aesthetically and functionally appealing for everyday use, and may therefore be 
more compatible with extended use than currently available actigraphy. Worn on the wrist, such 
devices measure motor activity via accelerometery, and some sample mean heart rate using 
photoplethysmography. Heart rate may provide an additional predictive signal, as cardiovascular 
regulation also expresses a circadian oscillation[18], and increased mean heart rate[19] and 
reduced variability[20, 21] have been associated with increasing severity of psychotic symptoms.  
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Crucially, most devices now communicate automatically and wirelessly with smartphones, thereby 
reducing the burden of data collection by allowing information to be uploaded over the mobile 
network and delivered to a researcher, clinician or patient in near real-time. Some manufacturers 
provide an Application Programming Interface (API), allowing researchers and software developers 
to access data directly from the company’s servers. The average cost of consumer wearable 
devices is a quarter to a third that of currently available research actigraphs. 
 
Accelerometers, gyroscopes, ambient light and other sensors within smartphones can also be 
harnessed to infer rest-activity patterns through the passive sensing of motor activity, geographical 
location, and phone usage, amongst other variables[22, 23]. Touchscreen technology facilitates 
the active capture of self-rated measures of symptomatology[24], as well as the delivery of 
psychological interventions[25] and information for promoting self-management[26]. Smartphone 
ownership and mobile data coverage continues to expand in developing and advanced 
economies[27], and mobile phone ownership has increased amongst people living with mental 
illness[28, 29]. mHealth approaches that employ wearable and smartphone technologies therefore 
show promise as innovative, cost-effective and scaleable ‘4P interventions’[30]  - predictive, pre-
emptive, personalised, and participatory - in the management of mental disorders in real-world 
settings.  
 
Although several studies have explored the feasibility and acceptability of smartphone 
interventions in schizophrenia[24, 26, 28, 31], wearable devices have received less attention. 
Studies using traditional actigraphy in schizophrenia have generally lasted in the order of several 
hours to days[15], to at most 28 days[7]. With regard to consumer devices, one study found good 
levels of adherence with a clip-on activity tracking device over a six-month period in individuals 
with a range of psychiatric diagnoses, eight of whom had schizophrenia-spectrum diagnoses[32]. 
However, these findings were in the context of promoting weight loss and physical activity, and did 
not examine 24-hour adherence. Whether the longer-term, continuous use of wearable devices is 
acceptable to individuals with schizophrenia has not been studied. Schizophrenia is associated 
with paranoid beliefs and impairments in motivation and cognition, which may interfere with 
engagement with mobile and wearable technologies. There also exist considerable challenges 
surrounding device validation, and the regulatory and ethical frameworks for employing consumer 
devices in clinical contexts[33].  
 
The Sleepsight study 
 
This pilot study represents the first stage in an ongoing program of research for applying wearable 
and smartphone technologies for the identification of early signs of deterioration in schizophrenia, 
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with a particular emphasis on passive sensing of rest-activity rhythms (Figure 1). The purpose of 
this paper is 1) to describe the user-centred development and implementation of a platform for 
sampling rest-activity profiles in schizophrenia; 2) to evaluate the feasibility, acceptability and user-
experience of the system in outpatients with schizophrenia, over an eight week period; and 3) to 
provide preliminary evidence demonstrating that meaningful passive behavioural parameters and 
self-rated subjective data can be captured using the platform. The mHealth Evidence and 
Assessment (mERA) checklist[34, 35] developed through World Health Organisation expert 
consensus for improving the generalisability and replicability of mHealth research, was used as a 
framework for synthesising and reporting this work.  
 
 
 
 
Figure 1. A theoretical overview of the approach, where continuous passive variables which have 
been shown to co-vary with severity of psychopathology, including rest-activity profiles and HR 
variability, are captured using digital technologies (bottom). Disturbances in these variables may be 
detectable in the early stages of relapse (top), thus providing a window for preventative 
intervention (w).  
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Methods 
 
Principles of platform development 
 
The Sleepsight platform was developed through collaboration between patients, clinicians, 
bioinformaticians and software developers, and was guided by the following core principles: 
 
1. User-centred design. People living with psychosis were involved throughout the development 
and testing cycle. Consultation groups consisted of patients who advised on the selection of 
wearable and mobile devices, the design of the software application, and aspects of the study 
design including recruitment strategy, feedback of data and incentivisation. The subsequent 
acceptability-feasibility study comprised a separate group  of patients living in the community.  
2. Integration with everyday life. Initial user-group testing with a range of currently available 
research wearables (GENEActiv, Activinsights, Cambridge, UK; ActiGraph GT9X Link, 
Actigraph corp, Pensacola, USA; Empatica E4, Milan, Italy) suggested that they would not be 
acceptable for extended use, due to their design and limited functionality. To enhance 
acceptability and minimise user burden and stigma, widely available consumer-oriented 
technologies were therefore considered. The user-groups favoured the wrist-worn Fitbit Charge 
HRTM (Fitbit Inc., San Francisco) due to its appearance as a lifestyle device, acceptably to both 
younger and older users, and the ability to view metrics relating to sleep and activity via the 
Fitbit app.  
3. Wireless functionality. The Fitbit provided wireless data transfer to a smartphone, and 
allowed access to minute-level activity, sleep and heart-rate data via API calls to the Fitbit 
server[36]. As with all consumer devices, data are pre-processed on the device in order to 
minimise the volume of data transfer and maximise battery life, which precludes access to raw 
sensor data. The Fitbit required charging approximately every five days, taking around two 
hours, and was splash-proof but not water-proof. An Android based Motorola Moto G second 
generation smartphone was selected due to its robust build quality, long battery life, relatively 
low cost and easy to read 5-inch screen.  
4. Remote and real-time. Each participant was provided with a 4G mobile data plan, which 
allowed data to be continuously uploaded to the research server, and adherence with the 
wearable device, sleep and symptom diary to be monitored in real-time. Participants with a 
home wireless network could also upload data via this route.  
5. Secure. Safeguarding privacy and data security was a cornerstone of the platform. Usernames 
were obfuscated using an MD5 hash algorithm[37], and data transmitted to the secure endpoint 
using SSL encryption, via the mobile network or the participant’s home wireless network. Data 
were cached on the phone until connectivity was available, and cleared from the device 
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following transmission. All participants received a unique identifier, and no personally 
identifiable digital information was stored or transmitted.  
6. Open source software. Code for the platform architecture is publicly available, in order to 
promote replicability, refinement of the software, and assessment of external validity through 
studies in other centres.  
 
The Sleepsight platform 
 
Sleepsight was developed around the Purple Robot[38-40] mobile application (Centre for 
Behavioural Intervention Technologies, Northwestern University, Chicago, USA); which allows real-
time data acquisition from a range of Android smartphone sensors, and integrates with wearable 
devices (figure 2). Purple Robot operates in the background, with no intervention from the user, 
and was configured to sample the smartphone accelerometer and light sensors, and access 
information about device battery level and the frequency of screen-unlock events (table 1). GPS 
location, call or text-message content were not captured, in response to advice from the user group 
that this would be perceived as intrusive for many users. Purple Robot consolidated data from two 
further sources: the wearable device - via API calls to the Fitbit server multiple times a day - and 
the Sleepsight app. Data are uploaded to the researcher-facing dashboard, where circadian 
patterns in rest-activity variables can be visualised in real-time (figure 3), and interruptions in the 
data stream identified and acted upon.   
 
The Sleepsight app[41] prompted the user, once a day at a time that was previously agreed with 
the study team, to complete a 30 second sleep diary (time to bed, time out of bed, and sleep 
quality) followed by a self-report symptom diary taking 2-3 minutes to complete. The purpose of the 
symptom diary was to provide an outcome measure of clinical status, against which associations 
with passive sensor variables could be examined. Each complete submission was followed by a 
short motivational message (e.g. ‘good job - see you tomorrow!’). The app also provided a help 
section with instructions on how to use the devices, and contact information in case of difficulties. 
 
Interoperability with existing local electronic patient clinical record systems was not supported at 
this stage, though future integration is planned.  
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Figure 2. Sleepsight platform architecture 
 
Table 1. Passive variables provided by the Sleepsight system. 
Wearable device 
sensors 
Output from sensor or variable 
Tri-axial accelerometer Raw data not available. Instead, several derived variables 
computed by Fitbit available: steps/ minute; lightly, moderately 
and very active minutes; sleep onset/offset/number of 
awakenings/total sleep time.  
Photoplethysmogram 
(optical sensor) 
Mean heart rate /min 
Smartphone sensors 
Tri-axial accelerometer Acceleration/g sampled at 10 Hz.  
Light sensor Ambient light intensity /lux 
Battery probe Battery level and charging events. 
Screen event probe Whether or not the screen was active.  
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Figure 3. Two sample variables from the researcher-facing dashboard, for a single participant. 
Upper panel: accelerometer output from smartphone showing periods of rest-activity over a 
continuous 36-hour period; lower panel: smartphone screen state, showing screen doze state 
(lower bars) and active screen state (upper bars) over seven days.  
 
 
Participants  
 
Fifteen adults with a diagnosis of schizophrenia were recruited through clinical teams from 
community psychiatric services in South London (Table 2). Inclusion criteria were ICD-10 criteria 
for schizophrenia, age between 18-65, and capacity to consent to research, and criteria for 
exclusion were gross cognitive, sensory or motor impairments that precluded the use of study 
devices. Participants were not selected on the basis of clinical status. Most had low-mild symptom 
intensity at baseline, as reflected in the total PANSS scores, however two participants were 
experiencing significant ongoing psychotic symptoms, with a PANSS positive sub-scale score 
above 20 (moderate intensity or greater on at least five of the seven items). Eight participants had 
negative symptoms sub scale scores of at least 20 (five of seven items moderate intensity or 
greater), and two greater than 25 (at least five items scored severe or greater). All were receiving 
antipsychotic treatment, and seven of the participants were prescribed clozapine, indicated in the 
UK for psychosis that is resistant to other antipsychotics. Eight participants lived alone, and seven 
lived with a spouse, children or wider family. None were in regular paid employment. All 
participants owned a mobile device of their own, and just over half had a touchscreen device. 
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Table 2. Clinical characteristics of participants at baseline 
 
Mean (SD) or n (%) 
Sex, n (%) 
 
 
Male 9 (60) 
 
Female  6 (40) 
Mean age (range) 44.1 (30-54) 
Mean duration of illness / 
years (range) 
16.6 (5-33) 
Mean PANSS score, (range, 
SD) 
 
 
Positive sub-scale  13.5 (7-23; 4.3) 
 
Negative sub-scale  19.7 (8-36; 7.5)  
 
General sub-scale  25.1 (16-40, 6.4) 
 
Total score  58.4 (32-81; 14.4)  
Medication, n (%) 
 
 
Clozapine 7 (47) 
 
Oral antipsychotic 5 (33) 
 
Depot antipsychotic 3 (20) 
Mobile device ownership, n 
(%) 
 
 
Non-touchscreen mobile 
phone 
7 (47) 
 
Touchscreen smartphone 8 (53) 
 
 
 
Study procedures 
 
Screening for eligibility and all clinical assessments were undertaken by an experienced 
psychiatrist (NM). Participants were asked to use the system continuously for eight weeks, during 
which time passive sensing and symptom rating variables were collected remotely.  
 
On enrolment, informed consent and psychiatric, medical and sleep histories were obtained. The 
PANSS, Pittsburgh Sleep Quality Index[42], Insomnia Severity Index[43] and Morningness-
Eveningness Questionnaire[44] measures were completed. Participants were provided with the 
study devices and cables and adaptors for charging, and a 4G mobile contract with 5 GB data 
allowance per month. Participants received an individual 45-minute face to face training session 
where use of the smartphone, Sleepsight app, wearable device and its synchronization were 
explained. They were asked to wear the Fitbit on the non-dominant wrist at all times, except for 
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when bathing or swimming, and were advised to charge the smartphone once a day, when going 
to bed, and to charge the device every 4-5 days. It was explained that the purpose of the study 
was to assess feasibility and acceptability, and therefore putative markers of relapse would not be 
monitored or responded to during the study.  
 
In addition to the provision of a mobile data plan, it was explained to participants on enrolment that 
they would be given the option of keeping the wearable device and smartphone on study 
completion, in order to provide an incentive for engagement and completion, and compensation for 
their time. However, the equipment would remain the property of the research team for the duration 
of the study, and they would be asked to return them if they withdrew before study completion. This 
strategy was formulated with user groups, and felt to be a fair and appropriate approach.  
 
The eight-week data collection period then began, and participants were free to use the 
smartphone for making calls, messages and web browsing. Participants were asked to use the 
study smartphone as their primary device, and where necessary their pre-existing telephone 
number and personal information was transferred to the new device. Participants received once 
weekly, personalised encouragement text message, with the aim of promoting motivation and 
engagement with the research team, and participants were instructed not to perform any updates 
to the Fitbit firmware duing the course of their participation. Data from each user was monitored on 
a daily basis. Where there was evidence of continued non-adherence for two or more days - e.g. 
no signal from wearable device - a SMS message prompt was sent to the participant, followed by 
telephone contact if necessary.  
 
Outcome measures 
 
Feasibility, was defined as the proportion of participants using each element of the system 
(wearable device, sleep log, symptom log) for at least 70% of the eight-week study period. 
‘Definitely feasible’ was defined as ≥70% participants meeting this criteria; ‘possibly feasible’ as 50-
69% participants; and ‘not feasible’ - as <50% of participants.  Removal of the wearable device 
was detected by absence of the heart-rate signal. In a test conducted separately (see 
supplementary material), absence of heart-rate signal was found to be a highly valid proxy for non-
wear.  
 
The symptom diary items were developed and validated in schizophrenia in the Clintouch study[24] 
against the Positive and Negative Syndrome Scale (PANSS)[45], and consisted of items relating to 
mood, anxiety, hallucinations, grandiosity and paranoia. 
 
Acceptability and usability were assessed at the end end of the study using a questionnaire 
conducted in person, adapted from previous studies[26] (table 3, supplementary material). 
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Subsequent discussion of user experiences arising from the questionnaire and were transcribed 
verbatim during the interview, to further explore attitudes and individual experiences towards the 
technology.  
 
Data analysis 
 
Quantitative analyses were undertaken in R[46].Associations between clinical parameters at 
baseline (PANSS positive score, PANSS negative score, and age) and adherence to wearable 
device, sleep and symptom diaries were calculated using Spearman’s correlation coefficients for 
non-parametric data.  
 
End of study questionnaires are reported descriptively. Interview transcripts were cross-checked 
for accuracy by a second researcher. Analysis of qualitative end of study user experiences 
followed a grounded-theory approach[45], using a coding frame based on major and minor 
categories emerging from the data, which was refined through discussion between two research 
clinicians.  
 
Ethical approval was obtained from the Dulwich Research and Ethics Committee, London, UK. As 
a research study which didn’t alter routine clinical care, with no intention of commercialisation, 
national regulatory approval from the Medicines & Healthcare Regulatory Agency (MHRA) was not 
required at this stage. 
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Results 
 
Adherence and feasibility 
 
Fourteen out of 15 participants completed the study, with varying levels of adherence to each 
element of the system. One participant withdrew from the study at the end of week one due to 
finding the wearable device uncomfortable, particularly in bed, and returned the study devices. 
They did not report suspicion towards the devices as a cause of discontinuation, and had a low 
total PANSS score of 47. Rather than adopting the study phone, one participant wished to continue 
to use her own smartphone, and it was therefore agreed that they would use this in parallel with 
the study device. The mean monthly data volume generated by the system per participant was 
~1.1 GB, not including personal data use. One participant used the monthly data allocation within 
the first three weeks, and was provided with an unlimited data plan for the remainder of the study. 
There was no loss or damage to devices.  
 
For the wearable device, all of the participants exceeded the 70% threshold for feasibility, with a 
mean wear-time of 21.8 hours/day, or 91% of the total study duration.  
 
For the Sleepsight app, 13/14 (93%) of participants met the feasibility criteria for completion of the 
daily sleep diary, with 91% of all possible questionnaires being completed. 12/14 (86%) of 
participants met the feasibility criteria for completion of the symptom diary, with 88% of all possible 
questionnaires being filled (figure 4). Participants 4 and 14, whose sleep and symptom diary 
completion rate was at or below the feasibility threshold, scored 29 and 36 respectively on the 
negative symptoms scale of the PANSS, consistent with negative symptoms in the severe range, 
and both had a history of treatment resistant illness. Participant 4 received four further weekly top-
up training sessions after reporting difficulties in completing the diaries and using the smartphone 
for making calls and sending SMS messages.  
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Figure 4. Overall adherence to wearable device, sleep and symptom diaries for each participant.  
 
Spearman correlation demonstrated a significant negative relationship between PANSS positive 
score and sleep diary completion (rs = -.49, P < .05), symptom diary completion (rs = -0.40, P 
< .01). PANSS negative score was negatively correlated with wearable adherence (rs = -.49, P 
< .05), sleep diary completion (rs = -.75, P = .001) and symptom diary completion (rs = -.53, P 
<.05). Associations between age and adherence with diaries and wearable device were non-
significant.  
 
Although adherence to the wearable device remained relatively stable throughout the eight-week 
study period, sleep and symptom log completion dropped off towards the latter quarter of the 
study, though remaining mostly above 70% (Figure 5).    
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Figure 5. Mean longitudinal adherence to wearable device, sleep and symptom diaries for all 
participants over the eight-week study period.  
 
End of study acceptability and usability findings 
 
Overall, responses to the end of study questionnaire relating to the Sleepsight system and each of 
its elements were positive (supplementary material, table 3). Fourteen participants completed the 
end of study interview: the majority found the system to be easy to grasp and use, though one 
participant found it complicated. 64% of participants expressed a wish to continue using the system 
in its current state, and 79% felt that sleep monitoring could be a successful strategy for the early 
detection of relapse.  
 
All participants found the personalised encouragement text messages to be helpful in improving 
motivation. 71% of users were motivated by the prospect of receiving devices at the end of the 
study, and a similar proportion reported frequently using the Fitbit app to view their sleep and 
physical activity patterns. All participants expressed a wish to keep the study devices after the 
study had ended. Three participants reported feeling occasionally suspicious towards the 
technology and worried that their personal information was at times being monitored. However, this 
did not lead to discontinuation.  
 
Thirteen of the 14 participants reported an inverse association between poor sleep and their 
mental wellbeing, and 12 of the 14 reported significant sleep disturbance around the time of their 
first episode of psychosis, or subsequent relapse. 
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Further themes extracted from the end of study interview clustered around three major themes: 
attitudes and beliefs towards the concept of remote sensing for predicting relapse; factors relating 
to the technology; and factors relating to the user’s illness in interacting with digital technologies.  
 
1. Attitudes and beliefs relating to remote sensing and relapse prediction. All but one 
participant reported experiences of sleep disturbance as an important problem, either during 
periods of stability and around episodes of acute illness, and welcomed the emphasis on sleep 
as a possible predictor of deterioration. Many felt that measuring sleep patterns would be an 
important element of self-management, and could imagine how psychological or 
pharmacological interventions delivered in the early stages of relapse could be therapeutic. 
Five participants commented how they would have concerns over false alarms - for example 
whether sleeping poorly in the absence of deterioration in symptoms would trigger a response. 
One preferred the terms sleep ‘tracking’ or ‘logging’ rather than ‘monitoring’, which held 
connotations of surveillance. Four participants felt that their engagement in the study was 
influenced by the knowledge that their data was not being analysed and responded to in real 
time, and if this were to have been the case, they would have greater levels of engagement.  
2. Technology related factors. Half of the users commented that the wearable was at times 
uncomfortable: the strap could feel tight, which was particularly bothersome in bed. However, 
most reported initial discomfort which improved as the study progressed. One reported 
intermittent concern over radiation emerging from the optical heart-rate monitor. There were no 
reports that the sleep metrics were inaccurate, however three participants felt the Fitbit 
overestimated step count. A third of participants found value in using the Fitbit for setting and 
attaining physical activity goals. Charging of the Fitbit or smartphone did not raise any 
concerns. Two-thirds of participants found that completing the daily symptom diary helped 
them reflect on mental state, and gain greater insight into the links between their symptoms 
and behaviours, especially sleep. A sense of being ‘acknowledged’ as a specific consequence 
of using the symptom diary was reported by three individuals. Two mentioned how it 
encouraged family to be involved, and became a focus for education. Six participants stated 
that the symptom diary became repetitive and tedious, particularly when the user felt their 
symptom burden was low, and that if there were no incentive, they would be unlikely to answer 
the questionnaire on a daily basis. Two users found some questions difficult to understand. A 
wish to have greater flexibility in the timing of diary completion was raised by two users.  
3. Illness related factors. A quarter of participants expressed concern that adherence would 
diminish during relapse. First, the user’s cognitive function and therefore ability to interact with 
the technology might decrease as symptoms escalate. Second, the user may develop 
suspicion towards the devices, leading to discontinuation. Generally, users felt that the 
wearable device would be better tolerated in this scenario than the smartphone diaries.  
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Comparison of subjective and objective estimates of rest-activity 
 
Correspondence between self-reported (sleep diary) and objective (Fitbit) determined daily time in 
bed for all participants showed good overall correlation (r = 0.50, P (two-tailed) < .001). At an 
individual level, 10/14 patients showed good agreement between subjective and objective 
measures, reaching the level of statistical significance (Figure 6). Participants 2, 4, 7 and 11 
showed poorer agreement between measures, which for participants 4,7 and 11 are likely to be 
due to the clustering of sleep diary estimates around the same value, suggesting that these 
participants gave stereotyped responses that varied little from day to day.    
 
 
 
Figure 6: Comparisons of subjectively (sleep diary) and objectively (Fitbit) determined daily time in 
bed for each participant, fitted with robust bisquare regression to account for outliers. *, ** 
Significance at the .05, <.01 levels, respectively, for the two-tailed test.  
 
More detailed visualisation of these data in two participants suggest that the Fitbit captured both 
within and inter-individual variability in rest-activity profiles. Figure 7 shows circadian variation in 
HR signal in a middle-aged participant treated with clozapine who led an active social life, with a 
regular circadian rhythm entrained to the light-dark cycle, and a younger participant, treated with 
aripiprazole, who spent considerable time in the bedroom, playing online computer games. This 
second case demonstrates a striking free-running non-24 hour circadian rhythm, with no 
correspondence to the light-dark cycle and progressive delay in sleep-onset – an observation 
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which has been previously reported in a single case report[47]. Subjective sleep times collected via 
the sleep diary, shown in green, suggest a close correspondence between subjective sleep times 
and objective rest-activity profiles in these participants. 
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Figure 7. Rest-activity profiles from two participants - one with regularly rest-activity profile (A-C) 
and another with a highly variable, free running circadian rhythm, not entrained to the day-night 
cycle (D-F). A and D: HR data from the wearable device, with darker shading indicating higher 
mean HR. B and E: subjective sleep times from sleep diary. C and F: subjective sleep times 
superimposed upon HR data (see main text for further details).      
Time of day (hours) 
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
A
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
B
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
C
E 
D
ay
 o
f s
tu
dy
 
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
A
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
B
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
C
D 
D
ay
 o
f s
tu
dy
 
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
A
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
B
12
:0
0:
00
12
:3
0:
00
13
:0
0:
00
13
:3
0:
00
14
:0
0:
00
14
:3
0:
00
15
:0
0:
00
15
:3
0:
00
16
:0
0:
00
16
:3
0:
00
17
:0
0:
00
17
:3
0:
00
18
:0
0:
00
18
:3
0:
00
19
:0
0:
00
19
:3
0:
00
20
:0
0:
00
20
:3
0:
00
21
:0
0:
00
21
:3
0:
00
22
:0
0:
00
22
:3
0:
00
23
:0
0:
00
23
:3
0:
00
00
:0
0:
00
00
:3
0:
00
01
:0
0:
00
01
:3
0:
00
02
:0
0:
00
02
:3
0:
00
03
:0
0:
00
03
:3
0:
00
04
:0
0:
00
04
:3
0:
00
05
:0
0:
00
05
:3
0:
00
06
:0
0:
00
06
:3
0:
00
07
:0
0:
00
07
:3
0:
00
08
:0
0:
00
08
:3
0:
00
09
:0
0:
00
09
:3
0:
00
10
:0
0:
00
10
:3
0:
00
11
:0
0:
00
11
:3
0:
00
D
ay
CF 
D
ay
 o
f s
tu
dy
 
   20 
Discussion 
 
Principal findings 
 
However sophisticated the engineering and analytic solutions, the success of digital interventions 
in improving clinical outcomes will depend crucially on whether they are adopted by patients for 
long-term use. We collaborated with patients in the design and deployment stages, and asked 
participants with severe mental illness, under the care of secondary level psychiatric services with 
a range of positive and negative symptom severity, to use wearable and smartphone devices over 
two months in a naturalistic, ecologically valid setting. Our findings suggest that people with 
schizophrenia are enthusiastic about the concept of sleep disturbance as an indicator of relapse, 
and are willing to adopt existing consumer technologies in managing their condition. Consistent 
with previous research examining smartphone interventions[26, 28, 31], we observed good levels 
of adherence with passive monitoring using wearable technologies over the study duration, across 
a range of ages and symptom severity. Adherence with active monitoring using smartphone diaries 
tended however to drop-off towards the latter quarter of the study, suggesting that passive 
monitoring was more acceptable to users. This raises questions about striking the correct balance 
when integrating passive and active approaches, each of which have their strengths, and how 
motivation with active monitoring can be maintained over time. In particular, users with significant 
negative symptoms experienced difficulties with completing the sleep and symptom diaries. 
Although some participants reported mild and intermittent suspicion, paranoia was not a cause of 
discontinuation. Similarly, there were very few concerns over data security and privacy, which may 
reflect the efforts that were made to build a trusting, collaborative relationship with participants.  
 
Motivation and incentives 
 
The relatively high rates of adherence in this study may be attributable to the incentives which 
were offered. Though all participants reported this as a motivating factor, the majority also reported 
intrinsic interest in the system, and wished to continue using it after the study ended. Nonetheless, 
enhancing engagement and motivation by providing the user with information that they value is a 
key challenge for the field. Each user is unique in which elements of the system they find engaging 
- some may value feedback on physical activity, others sleep duration, others their self-rated 
symptoms. Adaptable systems which can be tailored to each user may be a solution. Given this 
was an observational study, we opted against providing explicit feedback of passive sensor or 
diary data, due to its liability to influence on the underlying behaviour we aim to examine, however 
this may have reduced levels of adherence. Alternative approaches such as ‘gamification’[48] are 
attracting increasing interest.  
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Further, promoting motivation by providing relatively low-cost mobile communication technologies, 
which many patients may otherwise be unable to afford, may have the added benefit of enhancing 
social interaction, communication with the care team, and functioning. In a clinical scenario, should 
mobile technologies be shown to be effective in reducing relapse, provision of equipment and a 
mobile data contract would represent a relatively insignificant financial outlay in comparison to the 
personal, social and economic costs of relapse[49].  
 
Cost is also an important factor in considering the scalability and reach of digital interventions. The 
cost of the Fitbit Charge HR was £100, the Moto G smartphone £140, and the mobile data plan 
£14/month. The overall cost for consumables per user for the study was therefore £270, which 
equates to approximately just over half the cost of a day on an acute psychiatric ward[50], or the 
average cost of a monthly dose of paliperidone long-acting injectable antipsychotic medication[51]. 
As affordability and ownership of digital technologies grows in populations with SMI[28, 29, 52], 
this approach has the potential to address the disparities in healthcare provision in underserved 
populations with SMI globally [53]. 
 
Consumer devices in clinical research 
 
The use of consumer wearable device in clinical contexts raises several important considerations. 
These devices are marketed as products which claim to enhance fitness and wellbeing, often 
supported by bold but unsubstantiated claims. Although some validation data are published from 
healthy populations showing acceptable agreement between consumer devices to actigraphy for 
some physical activity measures[54] and sleep[55], and with ECG for heart-rate[56, 57], no such 
data are available for populations with psychosis. Do these devices, therefore, have a role as tools 
for clinical prediction?  
 
We suggest that they do, depending on the question being asked[58]. Our goal is not to draw 
conclusions about sleep parameters (e.g. total sleep time, sleep efficiency) per se, for which the 
use of unvalidated devices would be inappropriate. Rather, our objective is to ask whether changes 
in longitudinal rest-activity patterns at the within-person level, captured using wearable device and 
smartphone sensors, predict deterioration in clinical status. The measurement error of these 
devices in healthy populations is comparable to that of actigraphy[54, 55], and given the high level 
of noise inherent in free-living conditions, we hypothesise that should a signal exist, both consumer 
and research devices should be able to capture it. Comparison of subjective and objective 
estimates (figure 6) and visualisation of wearable data (figure 7) suggests that consumer devices 
capture both inter- and within-individual variability in rest-activity patterns, and our subsequent 
work will primarily use within-person analyses to evaluate the association between these predictors 
and mental state, making calibration and inter-device reliability less of an issue.  
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Though we welcome further validation studies of consumer against gold-standard devices, 
consumer devices follow a rapid product cycle, meaning they are rapidly superseded by newer 
models. Deciding on which device to study, and in which clinical groups, is therefore challenging. 
Another issue is the closed nature of these devices: due to reasons of intellectual property, 
manufacturers do not publish the algorithms through which activity and sleep outputs are 
calculated, and the researcher generally lacks control over implementation of algorithm updates 
during the course of a study. Also, pre-processing of data on the consumer device limits their 
granularity to minute-level data, at best. In turn, this may constrain the choice of subsequent 
analysis, for example it is uncertain whether non-linear patterns of motor activity[59, 60] can be 
extracted from these data. 
 
In navigating these challenges, greater collaboration between medical and consumer device 
manufacturers - each of whom operate a fundamentally different business model, researchers and 
consumers will be necessary for driving innovation in this area. It is worth reiterating that research 
grade, wearable accelerometers which are acceptable for long term use do not currently exist, and 
further research is urgently needed to evaluate the reliability and validity of consumer wearable 
and mobile devices as clinical tools[61] Regardless of its accuracy, the clinical utility of a device will 
be limited if adherence is poor.   
 
Limitations 
 
This small pilot study was designed primarily to evaluate feasibility and acceptability in patients in 
remission, and at this stage we are unable to draw any conclusions about its potential for 
identifying early markers of relapse, or offer evidence of the validity of the signal from the wearable 
device. Our supplementary trial suggested that the absence of HR signal is highly correlated to 
non-wear, however movement of the device may activate the HR sensor, and there remains the 
possibility that spurious readings were produced while the device is removed from the wrist. 
Participants were in a relatively stable phase of illness, and the influence of worsening 
psychopathology on adherence was not examined directly. Future studies should aim to test 
adherence over longer periods, in more unstable populations, such as in the period following 
hospitalisation[62]. Although a young-person’s user group was consulted in the development 
phase, the field study did not include younger adults under the care of early-intervention services. 
This group are particularly likely to benefit from early intervention strategies, and also engage well 
with digital interventions. The name of the study, which emphasised sleep in psychosis, may have 
led to a bias towards the recruitment of participants who experienced difficulties with sleep, which 
may have improved acceptability. However, this also illustrates the importance of designing 
interventions which address clinical problems which patients perceive to be important, and framing 
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them as such. We did not test the acceptability of collecting GPS location data, which recent 
studies suggest may be a useful feature in predicting clinical status in bipolar disorder[63]. As rates 
of smartphone ownership amongst people with mental illness grow, the incentive value of providing 
patients with smartphones may diminish.  
 
Conclusions and future directions 
 
We found enthusiasm and high levels of engagement with passive monitoring in people with 
schizophrenia which exceeded our acceptability thresholds, across a range of ages, symptom 
dimensions and severity. However, mHealth technologies are unlikely to be acceptable to all 
patients, and it will therefore be important to further understand which groups are most likely to 
engage with and benefit from these interventions, while maximising their reach by developing 
adaptable, tailored tools. An inherent property of participatory interventions is that they are likely to 
improve participants’ outcomes and relapse risk, for example by encouraging the user to reflect on 
their symptoms and monitor variables such as their sleep[64]. This has important implications in 
the design of future mHealth research, and argues for studies which detect improvement in 
outcomes in a randomised controlled, rather than a purely observational design.  
 
A further under-researched area is how the adoption of digital interventions by healthcare 
professionals can be facilitated[65] such that clinical decision-making is enhanced, rather than 
being perceived as an additional burden to an already busy schedule. Listening to the needs of 
clinicians in the co-design of technologies will be integral to their success, as will secure integration 
with existing medical record systems.  
 
Extracting clinically meaningful information in real-time from high-volume, multi-dimensional data 
represents another major challenge[66]. Although our interest focuses on circadian rest-activity 
profiles, combining additional sensor variables such as the ultradian organisation of motor 
activity[12, 59] and speech analysis[67] is likely to improve precision. The signature and optimal 
thresholds for relapse are likely to be different for each patient, and the inputs, sensitivity and 
specificity of algorithms will therefore need to be tuned to each individual. 
 
A long-term ambition of this approach is to enhance clinical care by identifying early signs of 
deterioration, and thereby facilitate self-management and preventative psychological or 
pharmacological intervention. As research in this area continues to advance, future efforts should 
focus upon how clinicians, patients, technologists and industry can work together effectively to 
maximize the clinical utility, validity and implementation of these novel tools. 
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